Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.35 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.35 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797174 | 0.87 | PRMT5 (0.41) | SLC18A3KCNH2HRH3MAPTMEN1 | |
| SCHEMBL30912540 | 0.87 | PRMT5 (0.41) | SLC18A3KCNH2HRH3MAPTMEN1 | |
| Trifluoroacetic Acid SCHEMBL3031403 | 0.83 | PRKAB2 (0.44) | SLC18A3SERPINE1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL900534 | 0.83 | SLC18A3 (0.50) | SLC18A3MAPTMEN1KMT2ADDB1 | |
| SCHEMBL5284 | 0.83 | SLC18A3 (0.50) | SLC18A3MAPTMEN1KMT2ADDB1 | |
| SCHEMBL1128088 | 0.83 | SLC18A3 (0.50) | SLC18A3MAPTMEN1KMT2ADDB1 | |
| Hydrochloric Acid SCHEMBL20543303 | 0.80 | SLC18A3 (0.48) | SLC18A3MAPTMEN1KMT2ADDB1 | |
| SCHEMBL1064153 | 0.78 | SLC18A3 (0.56) | SLC18A3SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL3484987 | 0.78 | SLC18A3 (0.52) | SLC18A3MAPTMEN1KMT2ADDB1 | |
| SCHEMBL10009777 | 0.78 | TNKS (0.42) | KCNH2HRH3SMN1; SMN2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-20240197729-A1 | ALK-5 Inhibitors and Uses Thereof | SUMITOMO PHARMA ONCOLOGY INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-03-14 | — | — | US | disclosed |
| EP-4313052-A1 | ALK-5 INHIBITORS AND USES THEREOF | Sumitomo Pharma Oncology, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117355304-A | ALK-5 inhibitors and uses thereof | 住友制药肿瘤公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4259145-A1 | ALK-5 INHIBITORS AND USES THEREOF | Sumitomo Pharma Oncology, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230286943-A1 | IL-17A MODULATORS | SANOFI (FR) | 2023-09-14 | — | — | US | disclosed |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-1249233-B9 | NPYY5 ANTAGONISTS | SHIONOGI & CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-1249233-B1 | NPYY5 ANTAGONISTS | SHIONOGI & CO (JP) | 2008-08-20 | — | — | EP | disclosed |
| US-4078076-A | HYPOLIPEMIC ACTIVITY | ROUSSEL UCLAF (FR) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197729-A1 | ALK-5 Inhibitors and Uses Thereof | ACVR1, ALK, ACVRL1 | SLC18A3 3988/4885KCNH2 3290/4885HRH3 2347/4885 |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | SLC18A3 4675/4885KCNH2 3013/4885HRH3 353/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | SLC18A3 487/4885KCNH2 3337/4885HRH3 3309/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | SLC18A3 1890/4885KCNH2 4733/4885HRH3 980/4885 |
| US-20230286943-A1 | IL-17A MODULATORS | IL17A, IL2, IL15 | SLC18A3 4688/4885KCNH2 4594/4885HRH3 3394/4885 |
| US-20240083895-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SLC18A3 2115/4885KCNH2 2622/4885HRH3 1666/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | SLC18A3 3774/4885KCNH2 2615/4885HRH3 1134/4885 |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | ACVR1, ALK, ACVRL1 | SLC18A3 4195/4885KCNH2 3382/4885HRH3 2119/4885 |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | SLC18A3 3358/4885KCNH2 3255/4885HRH3 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.